Funding Opportunities

NIH Funding Opportunities

Notice of an Update to the Award Information in RFA-AI-14-058 "Host-Directed TB Therapy: New Approaches (UH2/UH3)"
Notice NOT-AI-15-008 from the NIH Guide for Grants and Contracts
Mon, 24 Nov 2014 08:35:42 EST

NIA Coordinating Center for Genetics and Genomics of Alzheimer's Disease (U54)
Funding Opportunity RFA-AG-16-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to establish an NIA Coordination Center to facilitate and support the Replication Phase of the Alzheimer's Disease (AD) Sequencing Project (ADSP) activities. The Coordinating Center for the Genetics and Genomics of Alzheimer's Disease (CGAD) will serve as the focal point for ADSP replication phase joint data analysis, harmonization, and sharing. The FOA is intended to support a major component of the full range of analysis for the Replication Phase of the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on AD in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.
Tue, 25 Nov 2014 02:53:09 EST

Alzheimer's Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01)
Funding Opportunity RFA-AG-16-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications specific to targeted sequencing, genotyping, and data analysis in the Replication Phase of the Alzheimer's Disease Sequencing Project.
Tue, 25 Nov 2014 02:05:21 EST

Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
Funding Opportunity RFA-CA-15-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is an initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, prevention or treatment of cancers in humans living in LMICs. Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism. Applicants should have a working assay or prototype (not necessarily already capable of cancer applications). The initial UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones. UH2 projects that have met their milestones will be administratively considered by NCI and NIBIB and subsequently prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both UH2 and UH3 phases.
Mon, 24 Nov 2014 09:29:42 EST

Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (R41)
Funding Opportunity RFA-ES-15-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to develop medium- to high-throughput assays to evaluate the effects of toxicants on pluripotent or induced pluripotent cells with respect to cell differentiation and the resulting differentiated cell populations. The ability to incorporate genetic diversity in these assays would be useful.These assays will provide information on mechanisms of chemically-induced biological activity, help to prioritize chemicals for more extensive toxicological evaluation, support more predictive models of in vivo biological response, and potentially inform on the role of genetic diversity in toxicological effects.
Mon, 24 Nov 2014 10:41:06 EST

Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (R43/R44)
Funding Opportunity RFA-ES-15-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop medium- to high-throughput assays to evaluate the effects of toxicants on pluripotent or induced pluripotent cells with respect to cell differentiation and the resulting differentiated cell populations. The ability to incorporate genetic diversity in these assays would be useful.These assays will provide information on mechanisms of chemically-induced biological activity, help to prioritize chemicals for more extensive toxicological evaluation, support more predictive models of in vivo biological response, and potentially inform on the role of genetic diversity in toxicological effects.
Mon, 24 Nov 2014 10:40:49 EST

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01)
Funding Opportunity RFA-HL-16-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators.
Tue, 25 Nov 2014 03:14:01 EST

Underactive Bladder in Aging (R01)
Funding Opportunity PA-15-049 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of UAB with advancing age. Research supported by this initiative should enhance knowledge of UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of UAB in older persons.
Mon, 24 Nov 2014 03:35:47 EST

Underactive Bladder in Aging (R03)
Funding Opportunity PA-15-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of UAB in animal models and/or older adults;2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of UAB and its consequences in older adults and provide evidence of feasibility of the diagnosis, evaluation, and/or treatment of UAB in older persons.
Mon, 24 Nov 2014 03:35:38 EST

Underactive Bladder in Aging (R21)
Funding Opportunity PA-15-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of UAB in animal models and/or older adults;2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of UAB in older persons.
Mon, 24 Nov 2014 03:35:12 EST

Lab to Marketplace: Tools for Biomedical and Behavioral Research (R43/R44)
Funding Opportunity PA-15-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for biomedical or behavioral research from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnership and close collaboration between the original developers of these technologies and applicant SBCs, which may be accomplished in any of a number of ways, including the use of multiple principal investigators.
Mon, 24 Nov 2014 02:23:14 EST

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)
Funding Opportunity PAR-15-053 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to enhance the diversity of the NCI-funded research workforce by supporting and recruiting eligible investigators from groups that have been shown to be underrepresented in the biomedical, clinical, behavioral, and social sciences workforce. This funding opportunity will also provide a bridge to investigators that have completed their research training and may need extra time to develop a larger research project grant application.
Tue, 25 Nov 2014 02:05:45 EST